- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Nidek earns CE Mark for two new systems
Gamagori, Japan—Nidek has received CE Mark approvals to market its EC-5000 CXIII laser system and CV-7000 phaco system in the European market.
Gamagori, Japan-Nidek has received CE Mark approvals to market its EC-5000 CXIII laser system and CV-7000 phaco system in the European market.
The approvals, announced within 3 days of each other in mid-September, clear the way for the systems to be sold in Europe, the Middle East, and Asia.
The EC-5000CXIII combines the technological advances the company has made to its refractive surgery laser systems and incorporates them into one compact unit. The excimer laser platform functions as part of the company's NAVEX Quest System, with 200-Hz eye-tracking, torsion error detection and compensation, multi-point laser delivery, and proprietary software algorithms for custom refractive surgery.
The phaco system, which was launched at the European Society of Cataract and Refractive Surgeons meeting in Lisbon, Portugal, provides a high-repetitive pulse mode for reduced thermal heat, and offers peristaltic technology for fast set-up. A newly designed, reusable titanium handpiece delivers 40 kHz of ultrasound for phaco.
